JP Morgan downgraded Carlyle Group from Overweight to Neutral and set a new price target of $44.00 from $46.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
| 11/29/2023 | $32.00 | Outperform → In-line | Evercore ISI |
| 10/5/2023 | Peer Perform | Wolfe Research | |
| 5/19/2023 | $40.00 | Buy | Citigroup |
MCLEAN, Va., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced that Harish Nanda, the company's Chief Technology Officer, has been named a 2024 NVTC Tech100 Tech Executive honoree by the Northern Virginia Technology Council (NVTC). NVTC is one of the nation's largest technology councils, with a mission to establish the Northern Virginia region as a major global technology center. NVTC also recognized Acentra Health among Tech100 companies for driving innovation and supporting the region's economic growth.
Growth Driven By Solid Execution & Strength Across End Markets StandardAero (NYSE:SARO) announced results today for its third quarter ended September 30, 2024 ("Third Quarter 2024"). Third Quarter 2024 Highlights Revenue increased 13.2% year-over-year to $1,244.6 million Net Income was $16.4 million; Net Income Margin was 1.3% Adjusted EBITDA increased 26.0% year-over-year to $168.4 million Adjusted EBITDA Margin was 13.5%, an increase of 137 basis points compared to the prior year's quarter Capital expenditures were $25.3 million, reflecting continued investment in growth initiatives including the LEAP-1A/-1B program and the CFM56 Center of Excellence greenfield facility
MEMPHIS, Tenn., Nov. 12, 2024 /PRNewswire/ -- Sedgwick, a leading global provider of claims management, loss adjusting and technology-enabled business solutions, announced the closing of a significant minority investment in Sedgwick led by Altas Partners ("Altas"), a North American private equity firm, which was made public last month.Current investors, including funds managed by global investment firm Carlyle (NASDAQ:CG) and Stone Point Capital LLC, will remain as investors and continue to make significant new investments in the business, with Carlyle maintaining its control position in partnership with the investor group and the Sedgwick management team. Longtime investors CDPQ and Onex ar
4 - Carlyle Group Inc. (0001527166) (Issuer)
4 - Carlyle Group Inc. (0001527166) (Reporting)
3 - Carlyle Group Inc. (0001527166) (Reporting)
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00
Redburn Atlantic initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $55.00
JP Morgan downgraded Carlyle Group from Overweight to Neutral and set a new price target of $44.00 from $46.00 previously
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
10-Q - Carlyle Group Inc. (0001527166) (Filer)
N-PX - Carlyle Group Inc. (0001527166) (Filer)
SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its third quarter ended September 30, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "We delivered consistent performance in the third quarter of 2024, capitalizing on increased new deal activity and the strength of our existing portfolio companies. With another strong quarter of originations, we benefited from access to the broader Carlyle Global Credit Platform, as we supplemented our core cash flow strategy with differentiated deal flow and specialty lending
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Wednesday November 20, 2024, for its fourth quarter and full year 2024. CCIF will host a conference call at 10:00 a.m. EDT on Thursday, November 21, 2024, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally manage
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
MCLEAN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology solutions and clinical services company dedicated to helping government healthcare agencies accelerate better health outcomes, has named Brett Barton as Senior Vice President (SVP) of Client Experience. In this newly created role, Barton will represent the voice of the client across multiple touchpoints to deliver an exceptional experience that supports continued growth for the company and elevates the Acentra Health brand. Barton brings over three decades of experience in healthcare technology and services supporting the public sector and health and human services market. He comes to Acentra Health from Gainwell
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi